Jacques‐Eric Gottenberg

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Josef S Smolen, Robert Landewé, J. W. J. Bijlsma et al. · Annals of the Rheumatic Diseases · 2020 · 2.8K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S Smolen, Robert Landewé, Sytske Anne Bergstra et al. · Annals of the Rheumatic Diseases · 2022 · 1.8K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy

Mark C. Genovese, Kenneth Kalunian, Jacques‐Eric Gottenberg et al. · JAMA · 2019 · 327 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries

Axel Finckh, David Neto, Juan J. Gómez‐Reino et al. · Annals of the Rheumatic Diseases · 2014 · 317 citations

Medicine, Internal Medicine, Pharmacotherapy +15

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Marie Kostine, Axel Finckh, Clifton O. Bingham et al. · Annals of the Rheumatic Diseases · 2020 · 276 citations · Full text

Medicine, Immunology, Oncology +17